TETmedical, Inc, is a Delaware C-corp founded in December 2021 by Cornell Professors Alex Travis and Roy Cohen of Cornell University and Dr. David R. Fischell, a serial med tech entrepreneur and Cornell Trustee Emeritus. TET (Tethered Enzyme Technology) is based on more then $6 million in grant funding to professors Travis and Cohen including a prestigious NIH pioneer award. TETmedical has licensed the TET IP from Cornell University. TETmedical is actively completing development of its first product the Neuron Specific Enolase Functional Activity Stroke Test (NSE-FAST), to be the first in-vitro diagnostic for acute stroke. A pre-submission inquiry is already in process with the FDA, and the next phase of clinical testing is scheduled to begin in Q4, 2023. The NSE-FAST has the potential to provide a high sensitivity blood test for brain injury from stroke, with parallels to what tests for the biomarker troponin provide for heart attack, in terms of clinical workflow and utility.
